Cancer Cell

Article	Citations
Oxidative Stress in Cancer	1244
Conserved pan-cancer microenvironment subtypes predict response to immunotherapy	521
The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker	497
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities	427
Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion	389
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth	385
Engineering CAR-T Cells for Next-Generation Cancer Therapy	351
Proteogenomic and metabolomic characterization of human glioblastoma	323
The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes	312
Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer	288
Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments	284
Clinical Challenges of Immune Checkpoint Inhibitors	283
CD8+ T cells and fatty acids orchestrate tumor ferroptosis and immunity via ACSL4	280
Challenges and Opportunities for Pancreatic Cancer Immunotherapy	275
Type I collagen deletion in αSMA+ myofibroblasts augments immune suppression and accelerates progression of pancreatic cancer	274
Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma	272
Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade	269
Seroconversion rates following COVID-19 vaccination among patients with cancer	269
MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate	264
Cathepsin C promotes breast cancer lung metastasis by modulating neutrophil infiltration and neutrophil extracellular trap formation	260
Interactions between cancer cells and immune cells drive transitions to mesenchymal-like states in glioblastoma	255
Progressive immune dysfunction with advancing disease stage in renal cell carcinoma	237
Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial	221
Predicting Drug Response and Synergy Using a Deep Learning Model of Human Cancer Cells	219
Microbiome and cancer	218

Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies	216
Emergence of a High-Plasticity Cell State during Lung Cancer Evolution	211
Targeting cell-cycle machinery in cancer	210
YTHDF3 Induces the Translation of m6A-Enriched Gene Transcripts to Promote Breast Cancer Brain Metastasis	198
Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma	194
Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors	194
Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma	190
COVID-19 and Cancer: Current Challenges and Perspectives	188
Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer	186
Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial	185
Reduction of Liver Metastasis Stiffness Improves Response to Bevacizumab in Metastatic Colorectal Cancer	185
SARS-CoV-2 Viral Load Predicts Mortality in Patients with and without Cancer Who Are Hospitalized with COVID-19	185
Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liver	183
Immunometabolic Interplay in the Tumor Microenvironment	181
Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy	181
Spatially resolved multi-omics deciphers bidirectional tumor-host interdependence in glioblastoma	177
Mesothelial cell-derived antigen-presenting cancer-associated fibroblasts induce expansion of regulatory T cells in pancreatic cancer	174
Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma	170
Single-cell lineage tracing of metastatic cancer reveals selection of hybrid EMT states	170
Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade	168
Single-cell analysis defines a pancreatic fibroblast lineage that supports anti-tumor immunity	166
Single-cell dissection of cellular components and interactions shaping the tumor immune phenotypes in ovarian cancer	164
Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification	163
Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer	163
Mutant p53 suppresses innate immune signaling to promote tumorigenesis	160
Biomolecular Condensates and Cancer	158
Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations	157
Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer	156
Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL	155
Comprehensive Analysis of Genetic Ancestry and Its Molecular Correlates in Cancer	154
DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity	154
The Glioma Stem Cell Model in the Era of Single-Cell Genomics	151
Single-Cell Multiomics Sequencing Reveals Prevalent Genomic Alterations in Tumor Stromal Cells of Human Colorectal Cancer	145
Single-Cell Characterization of Malignant Phenotypes and Developmental Trajectories of Adrenal Neuroblastoma	143
An Embryonic Diapause-like Adaptation with Suppressed Myc Activity Enables Tumor Treatment Persistence	143
Artificial intelligence for clinical oncology	142
IL6/STAT3 Signaling Hijacks Estrogen Receptor α Enhancers to Drive Breast Cancer Metastasis	142
Epigenomic State Transitions Characterize Tumor Progression in Mouse Lung Adenocarcinoma	141
Immunomodulation by targeted anticancer agents	139
Immune phenotypic linkage between colorectal cancer and liver metastasis	137
Integrated Omics of Metastatic Colorectal Cancer	136
Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer	135
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial	135
Visualizing Synaptic Transfer of Tumor Antigens among Dendritic Cells	134
Inflammatory fibroblasts mediate resistance to neoadjuvant therapy in rectal cancer	130
Arsenic Trioxide Rescues Structural p53 Mutations through a Cryptic Allosteric Site	129
Tumor organoids: Opportunities and challenges to guide precision medicine	128
Artificial intelligence for multimodal data integration in oncology	128
Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer	126
Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma	125

Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma	124
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity	124
Activating a collaborative innate-adaptive immune response to control metastasis	124
Commensal bacteria and fungi differentially regulate tumor responses to radiation therapy	124
The loss of RNA N6-adenosine methyltransferase Mettl14 in tumor-associated macrophages promotes CD8+ T cell dysfunction and tumor growth	123
The CD155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer	123
Pan-cancer integrative histology-genomic analysis via multimodal deep learning	121
Fungal mycobiome drives IL-33 secretion and type 2 immunity in pancreatic cancer	120
Spatiotemporal co-dependency between macrophages and exhausted CD8+ T cells in cancer	118
Oncogenic extrachromosomal DNA functions as mobile enhancers to globally amplify chromosomal transcription	117
Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms	114
Functional precision oncology: Testing tumors with drugs to identify vulnerabilities and novel combinations	113
MLH1 Deficiency-Triggered DNA Hyperexcision by Exonuclease 1 Activates the cGAS-STING Pathway	113
Genome-wide CRISPR screens of T cell exhaustion identify chromatin remodeling factors that limit T cell persistence	111
SETD2 Restricts Prostate Cancer Metastasis by Integrating EZH2 and AMPK Signaling Pathways	111
Dietary Approaches to Cancer Therapy	109
N6-Methyladenosine on mRNA facilitates a phase-separated nuclear body that suppresses myeloid leukemic differentiation	109
Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress	109
The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma	108
Human prostate cancer bone metastases have an actionable immunosuppressive microenvironment	106
Extensive Remodeling of the Immune Microenvironment in B Cell Acute Lymphoblastic Leukemia	106
Reuterin in the healthy gut microbiome suppresses colorectal cancer growth through altering redox balance	102
Immunogenomic Landscape of Hematological Malignancies	101
Melanoma models for the next generation of therapies	100
Targeting pan-essential genes in cancer: Challenges and opportunities	99
MAT2A Inhibition Blocks the Growth of MTAP-Deleted Cancer Cells by Reducing PRMT5-Dependent mRNA Splicing and Inducing DNA Damage	99
The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1	99
Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies	98
Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy	98
Integrin αvβ6–TGFβ–SOX4 Pathway Drives Immune Evasion in Triple-Negative Breast Cancer	98
Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer	97
Single-Cell RNA-Seq Reveals Cellular Hierarchies and Impaired Developmental Trajectories in Pediatric Ependymoma	96
Multi-phenotype CRISPR-Cas9 Screen Identifies p38 Kinase as a Target for Adoptive Immunotherapies	96
Tim-4+ cavity-resident macrophages impair anti-tumor CD8+ T cell immunity	95
Mutant EZH2 Induces a Pre-malignant Lymphoma Niche by Reprogramming the Immune Response	94
Simultaneous targeting of TGF-β/PD-L1 synergizes with radiotherapy by reprogramming the tumor microenvironment to overcome immune evasion	93
Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study	93
Integrative analysis of drug response and clinical outcome in acute myeloid leukemia	92
Cholesterol Pathway Inhibition Induces TGF-β Signaling to Promote Basal Differentiation in Pancreatic Cancer	92
Cancer cells escape autophagy inhibition via NRF2-induced macropinocytosis	92
Integrated Metabolic and Epigenomic Reprograming by H3K27M Mutations in Diffuse Intrinsic Pontine Gliomas	91
Binary pan-cancer classes with distinct vulnerabilities defined by pro- or anti-cancer YAP/TEAD activity	91
Increased glucose metabolism in TAMs fuels O-GlcNAcylation of lysosomal Cathepsin B to promote cancer metastasis and chemoresistance	90
High-resolution single-cell atlas reveals diversity and plasticity of tissue-resident neutrophils in non-small cell lung cancer	90
Hematopoietic Progenitor Kinase1 (HPK1) Mediates T Cell Dysfunction and Is a Druggable Target for T Cell-Based Immunotherapies	88
Metabolic programming and immune suppression in the tumor microenvironment	86
Acute Immune Signatures and Their Legacies in Severe Acute Respiratory Syndrome Coronavirus-2 Infected Cancer Patients	86
Evaluation of cell-free DNA approaches for multi-cancer early detection	85
MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells	84
Evolutionary predictability of genetic versus nongenetic resistance to anticancer drugs in melanoma	83
Oncogenic collagen I homotrimers from cancer cells bind to α3β1 integrin and impact tumor microbiome and immunity to promote pancreatic cancer	83
Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy	80
Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer	80
Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy	79
Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia	79
Stanniocalcin 1 is a phagocytosis checkpoint driving tumor immune resistance	79
PKCλ/ι Loss Induces Autophagy, Oxidative Phosphorylation, and NRF2 to Promote Liver Cancer Progression	78
Anti-spike antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic malignancies	78
Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor	75
Immune checkpoint HLA-E:CD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance	75
Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma	74
Telomere Stress Potentiates STING-Dependent Anti-tumor Immunity	73
Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies	73
Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance	73
PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity	73
The Tumor Profiler Study: integrated, multi-omic, functional tumor profiling for clinical decision support	72
A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers	72
A High-Resolution Map of Human Enhancer RNA Loci Characterizes Super-enhancer Activities in Cancer	72
Exercise-induced engagement of the IL-15/IL-15Rα axis promotes anti-tumor immunity in pancreatic cancer	71
Selective Inhibition of STRN3-Containing PP2A Phosphatase Restores Hippo Tumor-Suppressor Activity in Gastric Cancer	70
From bench to bedside: Single-cell analysis for cancer immunotherapy	69
Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation	69
Cytokine Storms in Cancer and COVID-19	67
Serial assessment of measurable residual disease in medulloblastoma liquid biopsies	67
FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer	67
Epigenomic Reprogramming as a Driver of Malignant Glioma	67
Tumor heterogeneity	67
Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment	67
Senescence Reprogramming by TIMP1 Deficiency Promotes Prostate Cancer Metastasis	66
The m6A reader IGF2BP2 regulates glutamine metabolism and represents a therapeutic target in acute myeloid leukemia	66

Cell Lineage-Based Stratification for Glioblastoma	65
Oncolytic virotherapy-mediated anti-tumor response: a single-cell perspective	64
Neoantigen-specific CD4+ T cells in human melanoma have diverse differentiation states and correlate with CD8+ T cell, macrophage, and B cell function	64
GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity	63
Pan-cancer proteomic map of 949 human cell lines	62
The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance	62
Targeting RSPO3-LGR4 Signaling for Leukemia Stem Cell Eradication in Acute Myeloid Leukemia	60
Molecular classification and diagnostics of upper urinary tract urothelial carcinoma	60
Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory T cells	60
Multiomic analysis reveals conservation of cancer-associated fibroblast phenotypes across species and tissue of origin	60
Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis	59
Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma	59
Innate immune cells in the tumor microenvironment	59
IL-5-producing CD4+ T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer	58
Single-cell landscapes of primary glioblastomas and matched explants and cell lines show variable retention of inter- and intratumor heterogeneity	58
Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia	57
Unbiased Proteomic Profiling Uncovers a Targetable GNAS/PKA/PP2A Axis in Small Cell Lung Cancer Stem Cells	57
H3.3-K27M drives neural stem cell-specific gliomagenesis in a human iPSC-derived model	55
Activated fibroblasts in cancer: Perspectives and challenges	54
Transcriptomic profiles of neoantigen-reactive T cells in human gastrointestinal cancers	54
B cells and cancer	53
Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer	53
Cathepsin S Regulates Antigen Processing and T Cell Activity in Non-Hodgkin Lymphoma	53
Inflammatory Leptomeningeal Cytokines Mediate COVID-19 Neurologic Symptoms in Cancer Patients	53
Tumor microbiome links cellular programs and immunity in pancreatic cancer	51
The therapeutic window of antibody drug conjugates: A dogma in need of revision	51
COVID-19 mRNA booster vaccines elicit strong protection against SARS-CoV-2 Omicron variant in patients with cancer	51
Cancer Care Disparities during the COVID-19 Pandemic: COVID-19 and Cancer Outcomes Study	51
Precise reconstruction of the TME using bulk RNA-seq and a machine learning algorithm trained on artificial transcriptomes	51
The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients	50
STAG2 loss rewires oncogenic and developmental programs to promote metastasis in Ewing sarcoma	50
Interleukin-1 in tumor progression, therapy, and prevention	50
TRIM8 modulates the EWS/FLI oncoprotein to promote survival in Ewing sarcoma	50
STAG2 mutations alter CTCF-anchored loop extrusion, reduce cis-regulatory interactions and EWSR1-FLI1 activity in Ewing sarcoma	50
SETD5-Coordinated Chromatin Reprogramming Regulates Adaptive Resistance to Targeted Pancreatic Cancer Therapy	50
Spatial profiling technologies illuminate the tumor microenvironment	50
Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors	49
Leveraging self-assembled nanobiomaterials for improved cancer immunotherapy	49
Functional Genomics for Cancer Drug Target Discovery	47
Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer	46
Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy	46
Tumor-induced erythroid precursor-differentiated myeloid cells mediate immunosuppression and curtail anti-PD-1/PD-L1 treatment efficacy	46
Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness	46
Clinical application of advanced multi-omics tumor profiling: Shaping precision oncology of the future	46
TERAVOLT: Thoracic Cancers International COVID-19 Collaboration	46
Interferon-dependent SLC14A1+ cancer-associated fibroblasts promote cancer stemness via WNT5A in bladder cancer	46
Mapping single-cell transcriptomes in the intra-tumoral and associated territories of kidney cancer	46
Immune responses to COVID-19 vaccines in patients with cancer: Promising results and a note of caution	45
Cancer Patient Care during COVID-19	45
COVID-19: Staging of a New Disease	45
Isotype Switching Converts Anti-CD40 Antagonism to Agonism to Elicit Potent Antitumor Activity	45
MAX Functions as a Tumor Suppressor and Rewires Metabolism in Small Cell Lung Cancer	45
The translational challenges of precision oncology	45
The proteogenomic subtypes of acute myeloid leukemia	44
De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant glioma	44
Cancer immunotherapies transition endothelial cells into HEVs that generate TCF1+ T lymphocyte niches through a feed-forward loop	43
Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity	43
Neutrophil extracellular traps formed during chemotherapy confer treatment resistance via TGF-β activation	43
Humoral and cellular immune responses in SARS-CoV-2 mRNA-vaccinated patients with cancer	42
Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity	42
A covalent inhibitor of K-Ras(G12C) induces MHC class I presentation of haptenated peptide neoepitopes targetable by immunotherapy	42
Normal Somatic Mutations in Cancer Transformation	42
Integrated multi-omics profiling yields a clinically relevant molecular classification for esophageal squamous cell carcinoma	42
The role of exhaustion in CAR T cell therapy	40
Evaluation of TMB as a predictive biomarker in patients with solid cancers treated with anti-PD-1/CTLA-4 combination immunotherapy	40
The COVID-19 and Cancer Consortium: A Collaborative Effort to Understand the Effects of COVID-19 on Patients with Cancer	40
Transcriptome analysis reveals tumor microenvironment changes in glioblastoma	39
FOXA2 drives lineage plasticity and KIT pathway activation in neuroendocrine prostate cancer	39
Neutrophil-activating therapy for the treatment of cancer	39
High-performance multiplex drug-gated CAR circuits	39
NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer	39
New genomic technologies for multi-cancer early detection: Rethinking the scope of cancer screening	38
Large-Scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines	38
Elimination of fluorescent protein immunogenicity permits modeling of metastasis in immune-competent settings	38
Metabolic Imaging Detects Resistance to PI3Kα Inhibition Mediated by Persistent FOXM1 Expression in ER+ Breast Cancer	37
Tumor Mutational Burden as a Pan-cancer Biomarker for Immunotherapy: The Limits and Potential for Convergence	36
Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas	36
Cancer hallmarks intersect with neuroscience in the tumor microenvironment	36
Cancer Patients and Risk of Mortality for COVID-19	36
Efficacy of a third SARS-CoV-2 mRNA vaccine dose among hematopoietic cell transplantation, CAR T cell, and BiTE recipients	36
Expanding the Role for Immunotherapy in Triple-Negative Breast Cancer	35
Intersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy	34
A druggable addiction to de novo pyrimidine biosynthesis in diffuse midline glioma	34
Detection and localization of early- and late-stage cancers using platelet RNA	34
Ablation of the endoplasmic reticulum stress kinase PERK induces paraptosis and type I interferon to promote anti-tumor T cell responses	33
A Deregulated HOX Gene Axis Confers an Epigenetic Vulnerability in KRAS-Mutant Lung Cancers	33
Functional states of myeloid cells in cancer	33
NETworking with cancer: The bidirectional interplay between cancer and neutrophil extracellular traps	33
Challenges in neoantigen-directed therapeutics	32
Platelets control liver tumor growth through P2Y12-dependent CD40L release in NAFLD	32
Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy	32
MPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancer	32
Cancer cell autophagy, reprogrammed macrophages, and remodeled vasculature in glioblastoma triggers tumor immunity	32
Tumor PD-L1 engages myeloid PD-1 to suppress type I interferon to impair cytotoxic T lymphocyte recruitment	31
Impact of COVID-19 on case fatality rate of patients with cancer during the Omicron wave	31